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PharmacopeiaAbstract Introduction: Epoetin alfa (Eprex) is a subcutaneous, injectable formulation of short
half-life recombinant human erythropoietin (rHuEPO). To current knowledge there are no pub-
lished studies regarding the stability of rHuEPO once repackaging occurs (r-EPO) for clinical trial
purposes.Materials and methods:We assessed EPO concentration in Eprex and r-EPO syringes at
0, 60, 90, and 120 days after repackaging in polypropylene syringes. R-EPO was administered to 56
patients taking part in a clinical trial in Friedreich Ataxia. Serum EPO levels were measured at base-
line and 48 h after r-EPO administration. Results: No differences were found between r-EPO and
Eprex syringes, but both globally decreased in total EPO content during storage at 4 C. Patients
receiving r-EPO had similar levels in EPO content as expected from previous trials in Friedreich
Ataxia and from pharmacokinetics studies in healthy volunteers. Discussion: We demonstrate that
repackaging of EPO does not alter its concentration if compared to the original product (Eprex).
This is true both for repackaging procedures and for the stability in polypropylene tubes. The expi-
ration date of r-EPO can be extended from 1 to 4 months after repackaging, in accordance with
pharmacopeia rules.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).i Napoli
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Erythropoietin (EPO) is a 34 KDa glycoprotein, synthesized
by the kidney that stimulates erythropoiesis acting on erythro-
cyte precursors in the bone marrow (Jelkmann, 1992). Recom-
binant Human Erythropoietin (rHuEPO) is used for treatment
in anemic patients with chronic renal failure in whom the
endogenous production of EPO is impaired. It is used in
patients with chemotherapy-induced anemia (Galli et al.,
2015), reduces the need for blood transfusions in patients that
undergo surgery, and can also be used for patients at risk for
perioperative transfusions with anticipated significant blood
loss (McGirr et al., 2014).
Epoetin alfa (Eprex) is a subcutaneous, injectable formu-
lation and short half-life recombinant human erythropoietin.
It is produced by recombinant DNA technology in Chinese
Hamster Ovarian cells.
There are no published studies regarding the stability of
EPO, once repackaging occurs. Even the stability of the pro-
tein in polypropylene tubes has never been tested.
In our study, Eprex was aseptically repackaged in 1 mL
polypropylene syringes and stored at 4 C for up to 120 days,
and quantitative tests were performed. Repackaged EPO
(r-EPO) was administered to patients taking part to a clinical
trial, and serum levels were measured in order to confirm the
clinical utility of repackaging procedures.
2. Materials and methods
2.1. Preparation of syringes
Commercially available Eprex 40,000 IU/1 mL was pur-
chased from Janssen-Cilag (Milano, Italy), a subsidiary of
Johnson & Johnson (New Brunswick, NJ, USA). Each
Eprex batch used for tests had at least 18 months of shelf life
before expiration date. Eprex was delivered to ‘‘Farmacia
Ettore Florio snc”, an ISO 9001:2008 pharmacy, at controlled
temperature.
We performed drug-repackaging procedures following the
Italian pharmacopeia rules. For each preparation, Eprex
syringes were manually emptied in a sterile glass container
under a laminar flow hood. Eprex was aspirated in 1 mL
syringes (BD Micro-fine, 29G  12.7 mm, Becton Dickinson)
for a total volume of 1 mL (40,000 IU of EPO) or 0.75 mL
(30,000 IU of EPO), based on clinician’s request. Environment
air was checked during repackaging procedure using a portable
particle counter (Solair 3100, Lighthouse, Fremont, CA, USA).
The whole process was performed slowly in order to avoid
the introduction of air bubbles during the transfer phase. The
syringes were then sealed in vacuum sterile bags in order to
maintain sterility. Ten percent of each production, with a min-
imum of four syringes, was kept aside for microbiological
sterility testing, as prescribed by the pharmacopeia sterility
assay 2.6.1. This was performed at the Experimental Medicine
Department of the Second University of Naples, Italy.
2.2. Stability assay
For stability evaluation, eight 1 mL r-EPO syringes, from the
same batch preparation, were stored at 4 C for future assaysfor each time-point. In parallel, the same amount of syringes
of Eprex was retained at the moment of repackaging for
comparison. Both Eprex and r-EPO syringes were stored at
4 C up to 120 days.
The stability of r-EPO and EPREX was assessed by
enzyme-linked immunosorbent assay (ELISA) to detect
human EPO (Quantikine IVD Erythropoietin ELISA,
DEP00; R&D systems, Minneapolis USA) was used to assess
the EPO content, following manufacturer’s instructions.
The content of the syringes was expelled into 2-mL Eppen-
dorf tubes. Two serial dilutions of 1:100 and a final dilution of
1:40 were performed in order to obtain a final dilution of
1:400000. This matched the assay range of 2, 5–200 mIU/
mL, with an expected final concentration of 100 mIU/mL.
Results from ELISA measurements were multiplied by the
dilution factor for final results analysis.
2.3. Clinical trial design
The trial was approved form the local Ethics Committee
(256/11), registered at www.clinicaltrials.gov (NCT01493973),
and EUDRACT (2011-006156-37). The trial was performed
in accordance with the Declaration of Helsinki, European
guidelines CPMP/ICH/135/95, and Italian law D.
M.15/07/1997. All patients gave written informed consent
before any activity was linked to the clinical trial.
r-EPO was administered to patients taking part in a ran-
domized, placebo-controlled trial, to assess the effect of EPO
on exercise capacity in Friedreich Ataxia (FRDA) patients
(Sacca` et al., 2016). The trial is part of an extensive effort in
identifying drugs able to ameliorate the biochemical deficits
of FRDA (Boesch et al., 2007, 2008, 2014; Sacca` et al.,
2011). Briefly, 56 patients were randomized to receive r-EPO
(1200 IU/kg body weight subcutaneously) or equivalent dose
of placebo in a 1:1 ratio. Serum samples were obtained imme-
diately before the administration of r-EPO and 48 h later.
Samples were frozen at 80 C until analysis. Serum concen-
trations of EPO were measured using the same ELISA kit as
specified. Further details on the trial can be obtained at
www.clinicaltrials.gov (NCT01493973).2.4. Statistical analysis
For stability assays, data were analyzed using a General
Linear Model for repeated measures (GLM-RM). Within-
subjects factor was time, and four time-points were set. These
included baseline, 60, 90, and 120 days. Production method
(Eprex or r-EPO) was set as the between-subjects factor.
Simple repeated measure contrast was used with baseline as
the reference category. We calculated estimated marginal
means for the production and time interaction. Bonferroni
correction was applied for all repeated analysis. P values less
than 0.05 were considered significant. For serum EPO
concentration, we used a GLM-RM to analyze the effect of
time and r-EPO administration in the same way as the
stability assay. In addition, the effect of repackaging-to-
administration time was set as a covariate in order to test
its effect on serum EPO levels. Statistical analysis was per-
formed using SPSS version 22.0.0.1 running on MAC OSX
10.10.4.
Table 1 Eprex and r-EPO values are indicated as global mean ± SD; time and time  production significance is shown as baseline
versus other time-points; global significance of time is p< 0.01, and time  production is p= 0.592.
Eprex (IU/mL) r-EPO (IU/mL) Time (p) Time  production (p)
Baseline 46399.7 ± 6474 42910.3 ± 1501
60 days 42458.5 ± 821 48064.6 ± 327 0.736 0.343
90 days 34033.5 ± 2488 30223.5 ± 4088 0.007 0.933
120 days 33130.7 ± 2984 36625.5 ± 5031 0.092 0.717
Significant values are shown in bold characters (p< 0.05).
Figure 1 r-EPO = repackaged Erythropoietin.
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During storage at 4 C both Eprex and r-EPO globally
decreased in total EPO content. Global mean ± SD for both
Eprex and r-EPO was 44355 ± 4734 IU/mL at baseline,
45262 ± 3121 at 60 days, 32129 ± 3737 at 90 days, and
34296 ± 3696 at 120 days (overall significance p< 0.01).
The significance was driven by the contrast between baseline
and the 90 days time-point (Table 1 and Fig. 1; p= 0.007).
Interaction between time and production method was over-
all non-significant (p= 0.592), as well as the single contrasts
between baseline and the different time-points (Table 1,
Fig. 1).
During the clinical trial, baseline serum EPO was 15.1 ± 2
mIU/mL in the EPO group and 12.9 ± 1 in the placebo group
(p= 0.398). Forty-eight hours after drug administration,
serum EPO was 1489.5 ± 100 mIU/mL in r-EPO group, and
12.6 ± 1 in the placebo group (p< 0.001 for the interaction
of time and treatment).
Repackaging-to-administration time (RtA) was calculated
for all patients receiving r-EPO. This was 49.2 ± 23.5 days
(range 1–104). We then used RtA as a covariate in the serum
EPO GLM-RM. This did not produce significant results, indi-
cating that RtA did not influence serum EPO levels.
4. Discussion
When we started our trial, no stability tests were available for
repackaged EPO. As for pharmacopeia rules, the expirationdate was set at 30 days after repackaging procedures
(AAVV, 2008). Unfortunately, microbiological tests take up
to 14 days, thus reducing the window of use of every prepara-
tion to 14 days.
We demonstrate that repackaging of EPO does not alter its
concentration if compared to the original product (Eprex).
This is true both for repackaging procedures and for the stabil-
ity in polypropylene tubes. We considered a time frame up to
120 days; therefore, longer-term stability cannot be guaran-
teed. Nevertheless, considering that the normal shelf life of
original and generic EPO is 24 months, and that preparation
and microbiological tests may take up to 2 weeks, the remain-
ing three-and-a-half months are an acceptable window of use
for any clinical activity.
Similar results were recently reported for different inject-
able drugs. Stability studies have been performed after repack-
aging and storage of bevacizumab in polypropylene syringes
(Paul et al., 2012a). Bevacizumab was stable in its primary, sec-
ondary and tertiary structure for up to 90 days. Similarly
Rituximab and Trastuzumab were found to be stable up to
180 days after repackaging in polyolefin infusion bags (Paul
et al., 2012b, 2013).
We found higher EPO content than declared at baseline.
This is not surprising as it is similar to previous reported data
on Eprex (Park et al., 2009; Brinks et al., 2011). Unfortu-
nately, after 4 months of 4 C storage, EPO concentration
was 24% than baseline in the Eprex vials, and 17% in
the r-EPO vials. This is unexpected, and may not be attributed
to inadequate storage or transportation, as temperature log-
ging was regularly performed. End of shelf-life use can also
be out ruled as it was at least 18 months before expiration
for all batches of Eprex. To our knowledge no studies have
yet addressed this point, and future real-life studies may be
more informative.
Administration of r-EPO to patients increased serum EPO
concentration to a mean value of 1.5 IU/mL at 48 h after
administration of 1200 IU/kg subcutaneously. This is a similar
value to that previously reported in pharmacokinetics studies
(Ramakrishnan et al., 2004; Krzyzanski et al., 2005), and to
a previously reported trial with Eprex in FRDA patients
(Sacca` et al., 2011).
5. Conclusions
Repackaging of EPO in polypropylene syringes is possible and
does not alter the stability of the protein. This is confirmed
after in vivo injection during a clinical trial. The expiration
date of r-EPO can be extended up to 4 months after repackag-
ing, if allowed by the original expiration date.
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